Itamar Medical

What Itamar Medical does

Itamar Medical Ltd., operating as ZOLL Itamar, is an Israel-headquartered medical device company founded in 1997 and acquired by ZOLL Medical Corporation in 2021 (ZOLL itself being a subsidiary of the Japanese conglomerate Asahi Kasei). The company designs and sells the WatchPAT family of home sleep apnea testing (HSAT) devices, which use its proprietary Peripheral Arterial Tonometry (PAT) signal technology — a non-invasive measurement of arterial pulsatile volume changes at the fingertip — to detect respiratory events and compute AHI/RDI indices. The current product line spans the WatchPAT 300 (reusable), WatchPAT ONE (fully disposable, smartphone-connected), and the newly launched WatchPAT 400 (with arrhythmia/AFib detection, CSA detection, hypoxic burden, and SleePATh integration). Hardware sales are complemented by the CloudPAT cloud platform for study interpretation, the SleePATh digital questionnaire solution, and two managed-service programs — WatchPAT Direct and WatchPAT Solutions — where ZOLL IDTF handles prior authorization, billing, and reimbursement on behalf of the practice.

The company sells into three vertical customer segments: sleep medicine physicians and sleep centers (primary), cardiology and electrophysiology practices, and dental practices offering oral appliance therapy. Distribution is a direct enterprise sales model targeting healthcare professionals, supplemented by managed-service offerings that remove upfront capital and workflow burden for the practice. WatchPAT holds FDA 510(k) clearances and the PAT signal is an approved measure in the 2017 AASM HSAT Clinical Practice Guidelines; CloudPAT is SOC 2 Type II attested and ISO/IEC 27001:2022 certified. The legacy EndoPAT vascular-assessment product line was discontinued effective May 2025, and the WatchPAT 200 was discontinued in the US in August 2024, narrowing the portfolio around core HSAT.

Itamar operates globally with offices in Caesarea (Israel) and Atlanta (US), an EU authorized representative in Frankfurt, and commercial presence across the US, Canada, UK, Netherlands, France, Spain, and Australia. The WatchPAT 400 is currently available only in the Netherlands and the UK, while prior generations serve the broader footprint. The company has scaled to 101–250 employees and claims over three million sleep tests performed using its technology since 2006, supported by 900 peer-reviewed publications; pricing is not publicly disclosed and contracts are negotiated via direct sales inquiry.

Name

Itamar Medical

Legal name

Itamar Medical Ltd.

Website

https://itamar-medical.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Itamar Medical (ZOLL Itamar) designs and sells the WatchPAT family of home sleep apnea testing devices based on proprietary Peripheral Arterial Tonometry technology, serving sleep medicine, cardiology, and dental practices across the US, Canada, the UK, Europe, and Australia.

Ownership category

akta.pro rank

Product category

Sleep Apnea Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Home Health Care Services (62161), Home Health Equipment Rental (532283)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Testing Laboratories (8734), Services-Home Health Care Services (8082)

akta.pro primary industry

Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB)

akta.pro secondary industries

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE), Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF)

Keywords

• Home sleep apnea testing
• Sleep apnea diagnostics
• Cardiovascular diagnostics devices
• Peripheral arterial tonometry
• Medical diagnostic hardware

Headquarters

HQ city

Caesarea

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. WatchPAT Device Sales: Sale of hardware devices including WatchPAT 300, WatchPAT ONE (disposable), and WatchPAT 400. Devices are prescribed by healthcare providers and shipped to patients for home sleep apnea testing.
2. CloudPAT Software Services: Cloud-based platform subscription for secure patient data transfer, sleep study interpretation, and diagnosis. Healthcare providers access the platform to manage and interpret sleep studies.
3. WatchPAT Direct Program: Managed service where ZOLL handles patient scheduling, education, test completion, and study interpretation. Includes prior authorization, reimbursement, and billing handled by ZOLL IDTF.
4. WatchPAT Solutions Program: Full-service diagnostic solution for clinics with screening, prescribing, shipping, study upload, and billing managed by ZOLL. No financial burden on the practice.
5. Reimbursement and Billing: Company handles reimbursement and billing through ZOLL IDTF (Independent Diagnostic Testing Facility), navigating insurance coverage for sleep apnea diagnostic testing.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Itamar Medical designs, develops, and manufactures the WatchPAT family of home sleep apnea testing (HSAT) devices using proprietary Peripheral Arterial Tonometry (PAT) technology, complemented by the CloudPAT cloud platform for study interpretation and managed service programs (WatchPAT Direct and WatchPAT Solutions) that handle the end-to-end diagnostic workflow for healthcare providers.

Product overview

Itamar Medical, a division of ZOLL Medical, offers a unified portfolio of home sleep apnea testing (HSAT) solutions anchored by the WatchPAT family of devices. The product line centers on three generations of peripheral arterial tonometry-based diagnostic devices (WatchPAT ONE, WatchPAT 300, and WatchPAT 400) complemented by the CloudPAT cloud platform for data management and interpretation. Service offerings including WatchPAT Direct and WatchPAT Solutions provide end-to-end diagnostic program management. Advanced features such as SleePATh (digital questionnaire integration) and Arrhythmia Detection (AFib identification) extend core device capabilities. The company also offered the EndoPAT product line for vascular assessment, which has been discontinued as of May 2025.

Differentiator

Problem solved

Functional benefit

Brands

• WatchPAT: Home Sleep Apnea Test (HSAT) device line utilizing peripheral arterial tonometry technology for sleep apnea diagnosis. Includes WatchPAT 300, WatchPAT ONE, and WatchPAT 400 models.
• CloudPAT
• SleePATh
• PAT Technology

Products and services

• WatchPAT 300 Home Sleep Apnea Test (HSAT) device utilizing proprietary Peripheral Arterial Tonometry (PAT) signal for sleep apnea diagnosis. Includes Central Plus Module for Central Sleep Apnea identification. Sold to sleep medicine physicians, cardiologists, and dental practices for patient diagnostic use.
• WatchPAT ONE Fully disposable Home Sleep Apnea Test device with same accuracy and reliability as other WatchPAT products. Smartphone app transmits data to cloud. Sold to healthcare providers for at-home sleep apnea testing without capital investment.
• WatchPAT 400 Latest generation WatchPAT Home Sleep Apnea Test device with app-connected experience, arrhythmia detection (AFib and premature beats), Central Sleep Apnea detection, and hypoxic burden analysis. Sold to sleep medicine physicians and cardiologists in select markets.
• CloudPAT Cloud-based platform for secure patient data transfer, sleep study interpretation, and diagnosis management. Supports WatchPAT device connectivity and serves as the central hub for healthcare providers managing HSAT studies.
• WatchPAT Direct Streamlined HSAT service program allowing healthcare providers to reduce patient backlog with no upfront costs and minimal staff involvement. Company handles patient scheduling, education, kit shipping, and study completion.
• WatchPAT Solutions Comprehensive sleep apnea management program for clinics. Handles screening, prescribing, shipping, study management, prior authorization, reimbursement, and billing through ZOLL IDTF with no financial burden on the practice.

Quantifiable outcome

• ~98% success rate in sleep apnea testing
• +5 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Partnerships

One partnership is on record.

• ZOLL Medical CorporationcoreOthers · 1 January 2021ZOLL Itamar is a division of ZOLL Medical Corporation. Itamar Medical was acquired by ZOLL in 2021, making it a wholly-owned subsidiary. ZOLL Itamar leverages ZOLL's infrastructure for IDTF services, reimbursement handling, and distribution capabilities.

Scale indicators9 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• ResMed: Global leader in sleep-disordered breathing and CPAP/APAP therapy that also sells HSAT products and cloud platforms (e.g., myAir, AirView). Directly comparable to ZOLL Itamar because it competes in HSAT and shares the same prescriber base (sleep medicine, cardiology, dental), but operates at much larger scale with a full therapy portfolio.
• Koninklijke Philips (Philips Respironics): Major incumbent in sleep and respiratory care with the Alice NightOne HSAT device, PSG systems, and CPAP/BiPAP therapy. Overlaps with ZOLL Itamar's HSAT offering and the same sleep physician and cardiology customer base, while also bundling therapy products.

Direct peers

• Nox Medical: Icelandic-based developer of the Nox T3 portable sleep monitor and Nox SAS for HSAT/PSG. Directly comparable as a focused sleep-diagnostics device maker selling to sleep specialists and researchers, competing head-to-head with WatchPAT in HSAT workflows.
• CleveMed: US-based HSAT and PSG device maker (SleepView, Sapphire) targeting sleep specialists, dentists, and primary care. Comparable product offering (home sleep testing hardware plus cloud scoring) and similar target prescriber base as ZOLL Itamar's WatchPAT line.
• Compumedics: Australian sleep diagnostics company offering PSG and HSAT systems (Somfit, Somte) used in sleep labs, hospitals, and research. Directly comparable to ZOLL Itamar in sleep apnea diagnostics, with comparable channel to sleep physicians and researchers.
• SOMNOmedics: German manufacturer of portable sleep diagnostic systems (SOMNOwatch, SOMNOscreen) for HSAT, PSG, and ambulatory cardiorespiratory monitoring. Comparable as a focused sleep/cardiac diagnostics device vendor serving sleep specialists, cardiologists, and research centers.
• Natus Neuro / Natus Medical: Long-standing sleep diagnostics and neurophysiology device vendor (formerly Embla, Grass) selling PSG and HSAT systems to sleep labs and hospitals. Comparable as a multi-modality sleep diagnostics hardware provider with similar end customers as ZOLL Itamar.

Emerging players

• BMC Medical: Chinese medical device company with a growing HSAT and respiratory care portfolio (YH-series HSAT devices, CPAP). Comparable product overlap with WatchPAT in home sleep apnea testing, and an emerging global distribution presence overlapping ZOLL Itamar's international markets.
• Ectosense (NightOwl): Developer of the NightOwl disposable fingertip HSAT device with cloud-based AI scoring. Comparable as a fully disposable, app-connected HSAT that competes with WatchPAT ONE on ease of use and remote patient workflows.
• ApniMed: Sleep-focused company developing OSA pharmacotherapies and connected diagnostics for sleep specialists and cardiologists. Adjacent and emerging player addressing the same OSA patient population ZOLL Itamar targets via HSAT, though focused on pharmaceutical rather than hardware diagnostics.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/itamarmedical1
• Facebookfacebook.com/ItamarMedical
• LinkedInlinkedin.com/company/itamar-medical

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds12 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Itamar Medical